Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced its participation in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. This forum, organized by the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), brings together experts in nasal drug development to discuss the latest scientific and regulatory advancements. Silo's presence at the event signals the company's commitment to advancing its proprietary intranasal drug delivery platform, particularly for central nervous system (CNS) conditions.
CEO Eric Weisblum highlighted the strategic importance of the forum, stating that it provides an opportunity to engage with leading experts as Silo continues to advance SPC-15, its novel nose-to-brain therapeutic for the treatment of post-traumatic stress disorder (PTSD). The company has reported encouraging preclinical data for SPC-15, demonstrating that its formulation and delivery device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability findings, reinforcing the robustness of the product's formulation.
The development of SPC-15 is part of Silo's broader pipeline targeting underserved conditions, including stress-induced psychiatric disorders, chronic pain, and CNS diseases. The company's portfolio also includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets for Alzheimer's disease and multiple sclerosis, developed in collaboration with leading universities and laboratories. Silo's focus on intranasal delivery is particularly noteworthy, as this route offers a direct pathway to the brain, potentially improving efficacy and reducing systemic side effects compared to traditional oral or injectable therapies.
Participation in the IPAC-RS forum is a significant milestone for Silo, as it provides a platform to share its latest research and gather feedback from key opinion leaders in the field of nasal drug delivery. The event also offers networking opportunities that could foster future collaborations and partnerships. For investors, this announcement underscores Silo's active engagement in the scientific community and its progress in developing innovative treatments for conditions with high unmet medical needs.
The stability data for SPC-15 is a critical step towards regulatory filings, as it demonstrates the product's shelf-life and manufacturing consistency. By meeting predefined specifications, Silo is building a strong case for the viability of its intranasal platform, which could eventually be applied to other therapeutic areas. The company's participation in such forums also enhances its visibility among potential partners and investors, as it showcases the company's scientific rigor and commitment to addressing complex medical challenges.
As Silo Pharma continues to advance its pipeline, the insights gained from the IPAC-RS 2026 forum will likely inform future development strategies for SPC-15 and other intranasal candidates. The company's focus on underserved conditions, combined with its innovative drug delivery approach, positions it as a notable player in the biopharmaceutical landscape. For more information about Silo Pharma and its programs, visit the company's website at silopharma.com. The latest news and updates on SILO can be found in the company's newsroom at IBN's SILO newsroom.
